Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • erniewerner erniewerner Nov 6, 2013 9:36 AM Flag

    FoundationOne poster

    Clinical Next Generation Sequencing (NGS) Reveals High Frequency of Alterations
    to Guide Targeted Therapy in Lung Cancer Patients

    Presented last April. It is a bit biased to point out advantages to their proprietary diagnostic product, but is interesting and does discuss one Cabo patient.

 
EXEL
13.35-2.13(-13.76%)Sep 28 4:00 PMEDT